Publication: Vitamin D and Its Potential Benefit for the COVID-19 Pandemic
dc.contributor.author | Nipith Charoenngam | en_US |
dc.contributor.author | Arash Shirvani | en_US |
dc.contributor.author | Michael F. Holick | en_US |
dc.contributor.other | Siriraj Hospital | en_US |
dc.contributor.other | Boston University School of Medicine | en_US |
dc.date.accessioned | 2022-08-04T08:09:36Z | |
dc.date.available | 2022-08-04T08:09:36Z | |
dc.date.issued | 2021-05-01 | en_US |
dc.description.abstract | Vitamin D is known not only for its importance for bone health but also for its biologic activities on many other organ systems. This is due to the presence of the vitamin D receptor in various types of cells and tissues, including the skin, skeletal muscle, adipose tissue, endocrine pancreas, immune cells, and blood vessels. Experimental studies have shown that vitamin D exerts several actions that are thought to be protective against coronavirus disease (COVID-19) infectivity and severity. These include the immunomodulatory effects on the innate and adaptive immune systems, the regulatory effects on the renin-angiotensin-aldosterone-system in the kidneys and the lungs, and the protective effects against endothelial dysfunction and thrombosis. Prior to the COVID-19 pandemic, studies have shown that vitamin D supplementation is beneficial in protecting against risk of acquiring acute respiratory viral infection and may improve outcomes in sepsis and critically ill patients. There are a growing number of data connecting COVID-19 infectivity and severity with vitamin D status, suggesting a potential benefit of vitamin D supplementation for primary prevention or as an adjunctive treatment of COVID-19. Although the results from most ongoing randomized clinical trials aiming to prove the benefit of vitamin D supplementation for these purposes are still pending, there is no downside to increasing vitamin D intake and having sensible sunlight exposure to maintain serum 25-hydroxyvitamin D at a level of least 30 ng/mL (75 nmol/L) and preferably 40 to 60 ng/mL (100-150 nmol/L) to minimize the risk of COVID-19 infection and its severity. | en_US |
dc.identifier.citation | Endocrine Practice. Vol.27, No.5 (2021), 484-493 | en_US |
dc.identifier.doi | 10.1016/j.eprac.2021.03.006 | en_US |
dc.identifier.issn | 19342403 | en_US |
dc.identifier.issn | 1530891X | en_US |
dc.identifier.other | 2-s2.0-85105896407 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/76189 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105896407&origin=inward | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Medicine | en_US |
dc.title | Vitamin D and Its Potential Benefit for the COVID-19 Pandemic | en_US |
dc.type | Review | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105896407&origin=inward | en_US |